NVCR
Novocure LtdNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$2.04B
P/E Ratio
—
EPS
$-1.53
Beta
0.92
52W High
$18.92
52W Low
$9.82
50-Day MA
$14.99
200-Day MA
$13.23
Dividend Yield
—
Profit Margin
-25.70%
Forward P/E
909.09
PEG Ratio
-0.47
About Novocure Ltd
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Fundamentals
| Revenue (TTM) | $674.41M |
| Gross Profit (TTM) | $508.84M |
| EBITDA | $-166.22M |
| Operating Margin | -38.70% |
| Return on Equity | -50.00% |
| Return on Assets | -11.10% |
| Revenue/Share (TTM) | $6.00 |
| Book Value | $2.85 |
| Price-to-Book | 4.50 |
| Price-to-Sales (TTM) | 2.94 |
| EV/Revenue | 2.157 |
| EV/EBITDA | -6.92 |
| Quarterly Earnings Growth (YoY) | -6.00% |
| Quarterly Revenue Growth (YoY) | 12.30% |
| Shares Outstanding | $115.82M |
| Float | $95.25M |
| % Insiders | 10.01% |
| % Institutions | 88.42% |
Historical Volatility
HV 10-Day
80.11%
HV 20-Day
65.41%
HV 30-Day
65.75%
HV 60-Day
78.22%
HV Rank
59.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($26.29 target)
1
Strong Buy4
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026